Mymetics to manufacture HER-Vaxx cancer immunotherapy
Swiss-based Mymetics has agreed with Australian biotech Imugene to manufacture and develop its cancer immunotherapy HER-Vaxx, which is expected to enter into a Phase I/II clinical trial in 2015.
Archives for July 21, 2014
Pamplona CMO bullish about biopharma prospects after fundraising
3P Biopharmaceuticals has raised funds and announced plans to invest in its manufacturing capabilities to meet the needs of international clients.
Correction
Protein A OK! Repligen predicts growth in suit with MAb industry
Interest in creating alternatives to Protein A has waned in light of more viable cost-saving opportunities in bioprocessing, such as single-use adoption, says Repligen.
UPDATE
Sterile injectables M&A could indicate return to in-house production
Drugmakers are bringing sterile injectables capacity back in-house according to a Frost & Sullivan analyst, who says industry risk aversion is the key driver.